METABOLIC & WEIGHT RESEARCH / COLOPHON
About This Field Guide
A citation-anchored reading of three peptides sitting at three very different stages of evidence. No storefront. No clinic. No prescriptions.
What Peptides Long Island is
Peptides Long Island is a field guide to the published research on three peptides studied in connection with metabolic regulation and weight management: MOTS-c, retatrutide, and semaglutide, with semaglutide as the lead compound. The guide exists to make a scattered and often overstated body of research legible — to tell a reader, plainly and with citations, what each compound was actually studied for, in what population, and how far that evidence honestly reaches.
The organizing idea is deliberately uncomfortable: these three peptides sit at three genuinely different stages of evidence. One is an FDA-approved medicine with more than a decade of large clinical trials behind it. One is an investigational drug with two years of promising but unconfirmed Phase 2 data. One is a research-only peptide with essentially no completed human trial at all. Reading them side by side is more useful, not less, because of that gap — it shows plainly what separates a demonstrated human effect from an animal finding from a Phase 2 signal. Each compound has its own page; a comparison page lines up the three; a single shared references list aggregates every source used across the site.
How it is compiled
Two principles govern this guide. First, every research claim is anchored to a numbered citation on the references page — peer-reviewed journal articles, clinical-trial publications, and structural or mechanistic studies. Where a finding is a review rather than a primary study, or an observational association rather than an interventional trial, this guide says so explicitly.
Second, evidence is described at its actual strength and never inflated to make three unrelated peptides sound like a matched set. Semaglutide's trial results are reported in the population and duration in which they were studied. Retatrutide's Phase 2 figures are labeled as Phase 2, not treated as approved-label facts. MOTS-c's mouse and cell findings are described as exactly that — not extrapolated into a claim about what the peptide does in a person, because no such human evidence yet exists. Community-reported effects appear only where the underlying research corpus documents them, always under an explicit anecdotal label, and never with an attached dose.
What it is not
The name marks a place on the map, not a shingle over a door. Peptides Long Island keeps no dispensary and no exam room: it stocks no compound, fills no order, and holds no arrangement — paid or otherwise — with any drugmaker, telehealth outfit, or research-chemical seller. It names no diagnosis, writes no prescription, and sets no dose, timing, or route for anyone reading it.
The three compounds sit on different legal shelves, and the guide keeps them there. Semaglutide is an approved prescription medicine dispensed only through licensed providers. Retatrutide remains investigational, lawfully available only inside registered clinical trials. MOTS-c is sold strictly as a laboratory research chemical and is not meant for human use of any kind. Anyone weighing a personal decision belongs in a licensed clinician's office, not on this page. Notes on a citation, a correction, or a freshly published trial are welcome at the contact page; the one question this guide has to turn away is what a reader should take.